RLYB Rallybio Corp

Nasdaq rallybio.com


$ 0.69 nm (nm)    

Thursday, 13-Nov-2025 16:17:48 EST
QQQ $ 608.03 $ -12.68 (-2.04 %)
DIA $ 475.22 $ -8.02 (-1.66 %)
SPY $ 671.97 $ -11.34 (-1.66 %)
TLT $ 89.55 $ -0.74 (-0.82 %)
GLD $ 383.36 $ -3.12 (-0.81 %)
$ 0.6982
$ 0.64
$ 0.63 x 1,000
$ 0.71 x 1,000
$ 0.62 - $ 0.70
$ 0.22 - $ 1.24
394,622
na
29.49M
$ 0.57
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 03-13-2025 12-31-2024 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-12-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 03-06-2023 12-31-2022 10-K
13 11-07-2022 09-30-2022 10-Q
14 08-08-2022 06-30-2022 10-Q
15 05-10-2022 03-31-2022 10-Q
16 03-15-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 09-09-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 update-rallybio-q3-adj-eps-014-beats-021-estimate-sales-212000k-beat-66667k-estimate

Rallybio (NASDAQ:RLYB) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.21) by 3...

 rallybio-q3-eps-036-beats-021-estimate-sales-212000k-beat-66667k-estimate

Rallybio (NASDAQ:RLYB) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $(0.21) by 2...

 rallybio-completes-dosing-for-first-cohort-in-phase-1-confirmatory-pkpd-study-of-rlyb116-its-once-weekly-small-volume-subcutaneous-c5-inhibitor-being-developed-to-treat-rare-diseases

Rallybio Corporation (NASDAQ: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative...

 rallybio-q2-eps-022-beats-024-estimate-sales-212000k-down-from-299000k-yoy

Rallybio (NASDAQ:RLYB) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.24) by 1...

 why-is-microcap-rallybio-stock-trading-higher-on-tuesday

Rallybio sells its stake in preclinical HPP drug REV102 to Recursion in a deal worth up to $25 million, including equity and mi...

Core News & Articles

Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced th...

 rallybio-initiates-dosing-in-phase-1-confirmatory-pkpd-study-evaluating-rlyb116-subcutaneously-injected-c5-inhibitor

– Potential to Address a Broad Range of Complement-Mediated Diseases with Initial Focus on Immune Platelet Transfusion Refracto...

 rallybio-q1-eps-021-beats-026-estimate-sales-21200k

Rallybio (NASDAQ:RLYB) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.26) by 1...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION